Defendant
3 cases as defendant.
Tris Pharma, Inc. — Monmouth Junction, New Jersey (2031 US Highway 130). Founded in 2000 by Ketan Mehta, who remains President/CEO. Privately held; no public ticker. Third-party databases (PitchBook, Crunchbase-derived profiles) put headcount at roughly 500–580 employees, about two-thirds in New Jersey operations and one-third in US field roles. No verified public revenue figure.
Operations. Tris is a commercial-stage specialty pharmaceutical company built around oral modified-release drug delivery, principally its proprietary LiquiXR platform. Its commercial portfolio is concentrated in ADHD/CNS: DYANAVEL XR (amphetamine) extended-release liquid and tablet; Quillivant XR (methylphenidate ER oral suspension); QuilliChew ER (methylphenidate ER chewable tablet); and Ondya XR (clonidine ER oral suspension), a non-stimulant ADHD product. Quillivant XR and QuilliChew ER were co-developed with NextWave Pharmaceuticals, acquired out of Pfizer in 2019 via Tris's purchase of NextWave; NextWave Pharmaceuticals, Inc. is now a wholly owned Tris subsidiary. Tris also manufactures OTC and specialty generic products and out-licenses its delivery technology. It has a development-stage extended-release oxybate program (referred to in coverage as TRN-257) filed as a 505(b)(2) NDA, No. 220138.
Litigation posture. Tris is an operating company, not an NPE. All three tracked cases show it as defendant (0 as plaintiff) — a pure defense profile. All are variant captions of Jazz Pharmaceuticals Ireland Ltd. v. Tris Pharma, Inc., filed 2026-02-20, apparently two D.N.J. dockets (2:26-cv-01739 and 2:26-cv-01740) with a duplicate entry. The venue is Trenton, Tris's home district — not a plaintiff-friendly forum like the Eastern District of Texas.
Context. The suits are Hatch-Waxman/505(b)(2) actions in which Jazz alleges Tris's proposed extended-release oxybate product infringes patents listed for Jazz's Xywav, including mixed-oxybate-salt composition and concomitant-administration (divalproex) patents. Tris moved to dismiss; the court denied the motion on July 8, 2026. Litigation is ongoing; no merits judgment is reported.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.
Second Tris Pharma complaint filed after Tris's Jan 2026 notices of 505(b)(2) NDAs for Xyrem/Xywav generics. The narrative lists it among '306-family actions, though only 2:26-cv-01739 is expressly noted as identifying the '306 patent.
Jazz Pharmaceuticals Ireland Ltd. sued Tris Pharma, Inc. in the District of New Jersey. Judge Stanley R. Chesler denied Tris's motion to dismiss on July 8, 2026, and an answer, counterclaim, and scheduling order followed.